# Gene Editing For Sickle Cell Disease

> **NCT06506461** · PHASE1 · RECRUITING · sponsor: **St. Jude Children's Research Hospital** · enrollment: 25 (estimated)

## Conditions studied

- Sickle Cell Disease

## Interventions

- **DRUG:** Plerixafor
- **DRUG:** Busulfan
- **BIOLOGICAL:** Gene-modified CD34+ cells
- **DRUG:** Motixafortide

## Key facts

- **NCT ID:** NCT06506461
- **Lead sponsor:** St. Jude Children's Research Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-21
- **Primary completion:** 2029-12
- **Final completion:** 2032-12
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2026-05-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06506461

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06506461, "Gene Editing For Sickle Cell Disease". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06506461. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*